Moderna (MRNA) said Friday it has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for mRESVIA, its respiratory syncytial virus vaccine for adults 60 and over.
RSV is a highly contagious seasonal virus that causes lower respiratory tract infections and pneumonia, the company said.
The approval is based on the phase 3 ConquerRSV trial, which included around 37,000 adults aged 60 and older across 22 countries, the company said, adding that the trial found no serious safety concerns.
MRNA shares were 0.6% higher in recent trading.
Price: 31.28, Change: +0.19, Percent Change: +0.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.